ELUT
ELUTIA INC.
$0.9600
+0.31%
$42.4M
No data for this timeframe.
Vol
Market Cap$42.4M
Cap SizeNano Cap
Inst. Holders10 funds
Inst. Value$1.6M
Inst. Activity1 buys / 3 sells
Insider Activity2B / 0S
Insider Net $$95.0K
SEC Reports2
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001708527·Prev Close $0.9570
Recent Activity
Jun 11, 2026
other
Elutia to Present at Planet MicroCap Showcase 2026 on June 17th
Elutia presents at Planet MicroCap 2026, discussing its drug-eluting biomatrix technology targeting
Jun 10, 2026
Insider
Williams Michelle LeRoux acquired via exercise 12,500 shares
CHIEF SCIENTIFIC OFFICER
Jun 10, 2026
Insider
Williams Michelle LeRoux surrendered for taxes 4,269 shares
CHIEF SCIENTIFIC OFFICER @ $1.04 ($4.4K)
Jun 10, 2026
Insider
Ferguson Matthew acquired via exercise 12,500 shares
CHIEF FINANCIAL OFFICER
May 14, 2026
SEC
Elutia reported Q1 2026 revenue of $3.1M (+6% YoY) and a GAAP net loss of $7.5M, widening from a $3.9M loss in Q1 2025,
8-K — Impact 5/10
Mar 11, 2026
SEC
Elutia reported its 2025 financial results, highlighted by the $88 million sale of its BioEnvelope business to Boston Sc
8-K — Impact 7/10
Inst.
Alyeska Investment Group, L.P. — TRIM
1,281,172 shares ($887.5K)
Inst.
RENAISSANCE TECHNOLOGIES LLC — ADD
102,116 shares ($70.7K)
Price Targets
Historical data — last covering-analyst action Sep 2025. No current recommendation available.
$5.00 (Sep 2025)
Current $0.9600
Low $5.00
Median $5.00
High $5.00
1 analysts
$5.00
$5.00
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Sep 10, 2025 | Lake Street | MAINTAIN | Buy → Buy |
| May 9, 2025 | Lake Street | MAINTAIN | Buy → Buy |
| Mar 7, 2025 | Cantor Fitzgerald | REITERATE | Overweight → Overweight |
| Nov 15, 2024 | Cantor Fitzgerald | REITERATE | Overweight → Overweight |
| Sep 6, 2024 | Cantor Fitzgerald | REITERATE | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.15 | $-0.15 — $-0.15 | 35% YoY | 1 |
| Next Q | $-0.13 ▼ -8.3% | $-0.13 — $-0.13 | -44% YoY | 1 |
| Current FY | $-0.60 ▼ -11.1% | $-0.60 — $-0.60 | -169% YoY | 1 |
| Next FY | $-0.52 ▼ -2.0% | $-0.52 — $-0.52 | 13% YoY | 1 |
Latest Reports
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ROYAL BANK OF CANADA | — | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.1M | — |
| BlackRock, Inc. | $128.2K | — |
| VANGUARD FIDUCIARY TRUST CO | $125.3K | — |
| CITADEL ADVISORS LLC | $117.7K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 10, 2026 | Williams Michelle | M | $0.00 |
| Jun 10, 2026 | Williams Michelle | F | $4.4K |
| Jun 10, 2026 | Ferguson Matthew | M | $0.00 |
| Jun 10, 2026 | Ferguson Matthew | F | $4.7K |
| Jun 10, 2026 | Mills C | M | $0.00 |
10 institutional holders with $1.6M total value (1,492,260 shares) as of 2026-Q1. Top holders: ROYAL, VANGUARD, BlackRock,.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ROYAL BANK OF CANADA | 242 | $0.00 | 0.0% | — |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 1,023,699 | $1.1M | 68.6% | — |
| 3 | BlackRock, Inc. | 122,073 | $128.2K | 8.2% | — |
| 4 | VANGUARD FIDUCIARY TRUST CO | 119,345 | $125.3K | 8.0% | — |
| 5 | CITADEL ADVISORS LLC | 112,105 | $117.7K | 7.5% | — |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 82,716 | $86.9K | 5.5% | ADD +64.7% |
| 7 | STATE STREET CORP | 11,969 | $12.6K | 0.8% | — |
| 8 | Vanguard Global Advisers, LLC | 8,140 | $8.5K | 0.5% | — |
| 9 | MORGAN STANLEY | 6,971 | $7.3K | 0.5% | DOUBLED +298.6% |
| 10 | WELLS FARGO & COMPANY/MN | 5,000 | $5.3K | 0.3% | TRIM -68.6% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Alyeska Investment Group, L.P. | TRIM | 2,643,445 | 1,281,172 | -51.5% | $887.5K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 61,993 | 102,116 | +64.7% | $70.7K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | TRIM | 5,100 | 1,600 | -68.6% | $1.1K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 23,611 | 22 | -99.9% | $15.00 | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 37,016 | 61,993 | +67.5% | $55.2K | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 2,000 | 7,971 | +298.6% | $7.1K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 1,500 | 5,100 | +240.0% | $10.1K | 2025-Q2 |
| Alyeska Investment Group, L.P. | DOUBLED | 643,445 | 2,643,445 | +310.8% | $6.7M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 57,216 | 37,716 | -34.1% | $95.4K | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 1,000 | 2,895 | +189.5% | $7.3K | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 500 | 1,500 | +200.0% | $3.8K | 2025-Q1 |
| LAZARD ASSET MANAGEMENT LLC | TRIM | 400 | 202 | -49.5% | — | 2024-Q4 |
| VANGUARD GROUP INC | ADD | 499,045 | 932,735 | +86.9% | $3.5M | 2024-Q4 |
| CITIGROUP INC | TRIM | 18,511 | 9,662 | -47.8% | $36.1K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 12,235 | 500 | -95.9% | $1.9K | 2024-Q4 |
| Alyeska Investment Group, L.P. | DOUBLED | 91,977 | 643,445 | +599.6% | $2.5M | 2024-Q3 |
5 unique insiders with 17 transactions. Net insider value: $95.0K ($95.0K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 10, 2026 | Williams Michelle LeRoux | CHIEF SCIENTIFIC OFFICER | EXERCISE | 12,500 | — | — |
| Jun 10, 2026 | Williams Michelle LeRoux | CHIEF SCIENTIFIC OFFICER | TAX W/H | 4,269 | $1.04 | $4.4K |
| Jun 10, 2026 | Ferguson Matthew | CHIEF FINANCIAL OFFICER | EXERCISE | 12,500 | — | — |
| Jun 10, 2026 | Ferguson Matthew | CHIEF FINANCIAL OFFICER | TAX W/H | 4,485 | $1.04 | $4.7K |
| Jun 10, 2026 | Mills C Randal | PRESIDENT AND CEO | EXERCISE | 27,083 | — | — |
| Jun 10, 2026 | Mills C Randal | PRESIDENT AND CEO | TAX W/H | 9,718 | $1.04 | $10.1K |
| Jun 1, 2026 | RAKIN KEVIN | Director | J | 50,000 | — | — |
| Jun 1, 2026 | RAKIN KEVIN | Director | GIFT | 70,000 | — | — |
| Mar 10, 2026 | Ferguson Matthew | CHIEF FINANCIAL OFFICER | TAX W/H | 5,123 | $1.09 | $5.6K |
| Mar 10, 2026 | Ferguson Matthew | CHIEF FINANCIAL OFFICER | EXERCISE | 12,500 | — | — |
| Mar 10, 2026 | Williams Michelle LeRoux | CHIEF SCIENTIFIC OFFICER | TAX W/H | 4,613 | $1.09 | $5.0K |
| Mar 10, 2026 | Williams Michelle LeRoux | CHIEF SCIENTIFIC OFFICER | EXERCISE | 12,500 | — | — |
| Mar 10, 2026 | Mills C Randal | PRESIDENT AND CEO | EXERCISE | 27,084 | — | — |
| Mar 10, 2026 | Mills C Randal | PRESIDENT AND CEO | TAX W/H | 11,100 | $1.09 | $12.1K |
| Jan 30, 2026 | RAKIN KEVIN | Director | BUY | 70,000 | $1.06 | $74.2K |
| Jan 30, 2026 | NEELS GUIDO J | Director | BUY | 20,000 | $1.04 | $20.8K |
| Dec 10, 2025 | NEELS GUIDO J | Director | EXERCISE | 6,250 | — | — |
2 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 1 neutral. Avg impact: 6.0/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Sep 2025): 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Sep 2025. No current recommendation available.
$5.00 mean target (Sep 2025)
$5.00 Low
$5.00 High
| Metric | Value |
|---|---|
| Current Price | $0.9600 |
| Target Low | $5.00 |
| Target Mean | $5.00 |
| Target Median | $5.00 |
| Target High | $5.00 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.15 | $-0.15 | $-0.15 | 34.8% | +0.0% | 0↑ 1↓ | $0.0B | -53.7% | 1 |
| Next Q 2026-09-30 |
$-0.13 | $-0.13 | $-0.13 | -44.4% | -8.3% | 0↑ 1↓ | $0.0B | -9.7% | 1 |
| Current FY 2026-12-31 |
$-0.60 | $-0.60 | $-0.60 | -169.0% | -11.1% | 0↑ 1↓ | $0.0B | -2.4% | 1 |
| Next FY 2027-12-31 |
$-0.52 | $-0.52 | $-0.52 | 13.3% | -2.0% | 0↑ 1↓ | $0.0B | 9.2% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.150 | |
| 7d ago | $-0.150 | |
| 30d ago | $-0.150 | |
| 60d ago | $-0.150 | |
| 90d ago | $-0.120 | -0.030 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Sep 10, 2025 | Lake Street | MAINTAIN | Buy | Buy |
| May 9, 2025 | Lake Street | MAINTAIN | Buy | Buy |
| Mar 7, 2025 | Cantor Fitzgerald | REITERATE | Overweight | Overweight |
| Nov 15, 2024 | Cantor Fitzgerald | REITERATE | Overweight | Overweight |
| Sep 6, 2024 | Cantor Fitzgerald | REITERATE | Overweight | Overweight |
| Aug 8, 2024 | Cantor Fitzgerald | MAINTAIN | Overweight | Overweight |
| Jun 21, 2024 | Lake Street | MAINTAIN | Buy | Buy |
| Jun 20, 2024 | Cantor Fitzgerald | MAINTAIN | Overweight | Overweight |
| Jun 18, 2024 | Cantor Fitzgerald | MAINTAIN | Overweight | Overweight |
| May 10, 2024 | Cantor Fitzgerald | MAINTAIN | Overweight | Overweight |
| Nov 14, 2023 | Cantor Fitzgerald | MAINTAIN | Overweight | Overweight |
| Sep 28, 2023 | Lake Street | INITIATE | — | Buy |
| Sep 26, 2023 | Cantor Fitzgerald | REITERATE | Overweight | Overweight |
| Sep 19, 2023 | Cantor Fitzgerald | REITERATE | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 11, 2026
other
Elutia to Present at Planet MicroCap Showcase 2026 on June 17th
Elutia presents at Planet MicroCap 2026, discussing its drug-eluting biomatrix technology targeting post-surgical infection in breast reconstruction.
May 18, 2026
other
Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
<p>GAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix t
May 14, 2026
other
Elutia to Present at the 16th Annual LD Micro Invitational on May 18th
Elutia to present at the 16th Annual LD Micro Invitational May 18th at 11:30 am Pacific Time.
May 14, 2026
earnings_calendar
ELUT Q1 2026 Earnings Scheduled — 2026-05-14
May 7, 2026
earnings_calendar
ELUT Q1 2026 Earnings Scheduled — 2026-05-07
Mar 13, 2026
other
Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Mar 11, 2026
earnings
Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process
Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process
Mar 11, 2026
earnings_calendar
ELUT Q4 2025 Earnings After Market Close — 2026-03-11
Mar 4, 2026
earnings_calendar
ELUT Q4 2025 Earnings After Market Close — 2026-03-04